Elderly cancer patients with normal complete blood cell counts (CBCs) during the first course of (some types of) chemotherapy might be unlikely to experience grade 4 neutropenia during subsequent cycles. In this case, further weekly CBCs might be avoided.We used data of 223 cancer patients aged 70+ who were included in the CRASH (Chemotherapy Risk Assessment Score for High-age patients) trial between 2003 and 2007 in 7 cancer practices in the US. First cycle CBC values were compared to subsequent cycles. MAX2-score was used as a measure for toxicity of the chemotherapy regimen.Sixty-two patients (28%) experienced grade 4 neutropenia during subsequent cycles. Among patients who received chemotherapy with a MAX2-score lower than 0.20, only 4.6% of those without neutropenia during the first cycle experienced grade 4 neutropenia during subsequent cycles. Weekly CBC might be avoided in these patients receiving chemotherapy. Future prospective studies should confirm these results.

, , , ,
doi.org/10.1016/j.critrevonc.2010.07.001, hdl.handle.net/1765/23840
Critical Reviews in Oncology / Hematology
Erasmus MC: University Medical Center Rotterdam

Janssen-Heijnen, M., Extermann, M., & Boler, I. (2011). Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy?. Critical Reviews in Oncology / Hematology (Vol. 79, pp. 43–50). doi:10.1016/j.critrevonc.2010.07.001